 | Up a level |
Boy, C.; Poeppel, T.; Kotzerke, J.; Krause, B. J.; Amthauer, H.; Baum, R. P.; Buchmann, I.; Ezziddin, S.; Führer, D.; Gabriel, M.; Kuwert, T.; Lahner, H.; Lauenstein, T.; Maecke, H. R.; Nagarajah, J.; Rösch, F.; Scheidhauer, K.; Schmidt, M.; Walter, Martin Alexander and Bockisch, A. (2018). Somatostatinrezeptor-PET/CT. Nuklearmedizin, 57(01), pp. 4-17. Thieme 10.1055/s-0038-1636560
Romer, A.; Seiler, D.; Marincek, Nicolas; Brunner, P.; Koller, M. T.; Ng, Quinn Kwan-Tai; Maecke, H. R.; Müller-Brand, J.; Rochlitz, C.; Briel, M.; Schindler, C.; Walter, Martin Alexander (2014). Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 41(2), pp. 214-222. Springer 10.1007/s00259-013-2559-8
Oyen, W. J. G.; Bodei, L.; Giammarile, F.; Maecke, H. R.; Tennvall, J.; Luster, M.; Brans, B. (2007). Targeted therapy in nuclear medicine—current status and future prospects. Annals of oncology, 18(11), pp. 1782-1792. Oxford University Press 10.1093/annonc/mdm111
